ANOC 001
Alternative Names: ANOC-001; KRAS-G12V targeting TCR-T cell therapyLatest Information Update: 31 Mar 2025
At a glance
- Originator Anocca
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 17 Mar 2025 Regulatory body approves CTA application for ANOC 001 in Adenocarcinoma in EU
- 17 Mar 2025 Anocca plans a phase I/II VIDAR-1 multi-asset umbrella trial for ANOC 001 in Adenocarcinoma (Late-stage disease) (Parenteral) in Sweden, Denmark, Germany and Netherlands in second quarter of 2025
- 26 Nov 2024 Anocca files Clinical Trial Application with the European Medicines Agency for Adenocarcinoma